Education & Training

Medical School

Ohio State University College of Medicine


Surgery (General Surgery)

  • Washington University School of Medicine


Colon & Rectal Surgery

  • Lahey Clinic Medical Center


American Board of Surgery
American Board of Colon & Rectal Surgery


MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

Academic Information

Assistant Professor
P. 573-882-8454

Research Profile

University of Missouri oncologist Dr. Jonathan Mitchem is an expert on intestinal diseases.

Mitchem, who earned his medical degree with honors, is a skilled oncology surgeon. Among other specialties, he has expertise in the treatment of colorectal cancer — one of the most common cancers diagnosed in the United States. In addition to performing surgeries, Mitchem also writes articles detailing best surgical practices for patients with cancer, as well as polyps and other colon disorders.

Outside of the operating room, Mitchem also tackles colon and rectal cancers in his research. He is working to understand the best way to harness a patient’s own immune system to fight cancer by focusing on how the anti-tumor immune response develops.

Mitchem is an MU KL2 Clinical Research Scholar, a designation granted to outstanding junior faculty. Through a University of Missouri-Washington University partnership, co-funded by MU’s Institute for Clinical and Translational Science, Mitchem has received funding and mentorship to enhance his multidisciplinary clinical research.

Dr. Jonathan Mitchem is an assistant professor of surgery in the University of Missouri’s School of Medicine.

Download the Featured Profile

Research Interests

  • Colorectal cancer
  • Tumor Immunology
  • Immunotherapy
  • Crohn's Disease
  • Ulcerative Colitis

Areas of Expertise

  • Colorectal cancer
  • Tumor Immunology
  • Crohn's Disease
  • Ulcerative Colitis

Awards & Honors

  • 2018 Washington University Clinical Research Training Center Outstanding Citizenship Award
  • 2017 New Jersey Colon and Rectal Surgery Society Award for Excellence in Basic Science, American Society of Colon and Rectal Surgery Annual Meeting, Seattle, WA 
  • 2016 Featured presenter, Washington University Institute of Translational and Clinical Science Annual Research Symposium, St. Louis, MO
  • 2016 University of Missouri Clinical Research Scholar
  • 2016 2nd Place, Trainee Research Competition, New England Society of Colon and Rectal Surgeons 2016 Annual Meeting
  • 2015 Resident Teaching Award, Washington University School of Medicine, Department of General Surgery
  • 2014 The Best of the AACR Journals, One of the 4 Most Cited Articles in Cancer Research, 2013
  • 2011-2009 Resident Teaching Award, Washington University School of Medicine, Department of General Surgery
  • 2007 Carey Award in Surgery, The Ohio State University College of Medicine and Public Health
  • 2006 Alpha Omega Alpha Honor Society, The Ohio State University College of Medicine and Public Health
  • 2006 Phi Kappa Phi Honor Society, The Ohio State University College of Medicine and Public Health
  • 2006 Starling Ohio Women’s Club Scholarship, The Ohio State University College of Medicine and Public Health


  1. Mitchem JB, Stafford C, Francone TD, Roberts PL, Schoetz DJ, Marcello PW, Ricciardi R. What is the optimal management of an intra-operative air leak in the colorectal anastomosis? Colorectal Dis. 2018 Feb;20(2):039-045.
  2. Jones J, Bhanu S, Mitchem JB, Amos-Landgraf JM, Lewis MR. Use of a Tumor-targeting, Near Infrared Fluorescent Peptide for Early Detection and Endoscopic Resection of Polyps in a Rat Model of Colorectal Cancer. Molecular Imaging. 2018; Jan-Dec; 17: 1536012118790065.
  3. Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol Immunother. 2014 Mar; 63(5): 513-28. 
  4. Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. J Cancer Ther. 2013 May;4(3):797-803.
  5. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013 Jul 1;19(13):3404-15.
  6. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013 Feb 1;73(3):1128-41
  7. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013 Jun;31(3):707-13.
Download All Publications Download